Recruiting CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164 Conditions Acute Myeloid Leukemia With Gene Mutations, Bone Marrow Diseases, Hematologic Diseases, +12 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
Not Yet Recruiting Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients NCT07507760 Conditions Acute Myeloid Leukemia With Gene Mutations Locations Complejo Hospitalario de Albacete — Albacete, Spain Hospital General Universitario Dr. Balmis — Alicante, Spain Hospital Universitario de Burgos — Burgos, Spain Hospital San Pedro Alcántara — Cáceres, Spain View all 15 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 Conditions Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, +61 more Locations Thomas Jefferson University — Philadelphia, Pennsylvania, United States View Trial Details
Completed Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia NCT01904136 Conditions Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, +26 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
